| NCT05191667 | AN0025 and Chemoradiotherapy Combination in Esophageal Cancer | SUSPENDED | PHASE1 | 2022-01-18 | 2025-12 | 2025-12 |
| NCT05519059 | Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer | COMPLETED | PHASE1 | 2021-10-11 | 2023-05-30 | 2022-09-29 |
| NCT04999384 | First in Human, Dose Escalation Study of AN4005 | RECRUITING | PHASE1 | 2021-09-27 | 2025-12 | 2025-08 |
| NCT04975958 | Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors | COMPLETED | PHASE1 | 2021-09-07 | 2025-01-24 | 2025-01-24 |
| NCT04338399 | The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC | ACTIVE_NOT_RECRUITING | PHASE3 | 2020-12-12 | 2026-06-30 | 2025-06-30 |
| NCT04432857 | AN0025 and Pembrolizumab Combination in Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | PHASE1 | 2020-08-20 | 2025-01-30 | 2024-05-31 |
| NCT03152370 | Preoperative Radiotherapy and E7046 in Rectum Cancer | COMPLETED | PHASE1 | 2017-05-17 | 2021-09-30 | 2021-08-31 |